Novartis will license in a new drug it has been developing with Molecular Partners to treat Covid-19, the Swiss company said on January 10, after getting positive trial data.
Cyrus Biotechnology announced that the Seattle-based biotechnology firm’s pre-clinical stage COVID therapeutic lead molecule, ACE2.v2.4 strongly binds the spike protein of SARS-CoV-2 variant of concern (VOC) omicron.
The U.S. Food and Drug Administration authorized the emergency use of Pfizer Inc.’s Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of mild-to-moderate Covid-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Pfizer Inc . on December 14 said the company’s antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.